Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 721-736

  Tate, Mitchel ^a   Chong, Aaron ^a   Robinson, Emma ^a   Green, Brian D ^a   Grieve, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ANTIDIABETIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OBESITY; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84920778263     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12943     Document Type: Review

References (167)

1. Action to Control Cardiovascular Risk in Diabetes Study Group (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1607-1651.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14:Transporters. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
7. Amori RE, Lau J, Pittas AG (2007). Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206.
8. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T et al. (2010). Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59: 1030-1037.
9. Aronis KN, Chamberland JP, Mantzoros CS (2013). GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 62: 1279-1286.
10. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I et al. (2013). Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 154: 2501-2513.
11. Aroor AR, Sowers JR, Jia G, DeMarco VG (2014). Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol 307: H477-H492.
12. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606-1616.
13. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean M et al. (2012). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36: 843-854.
14. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T et al. (2013). Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2: e003277.
15. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S, Drucker DJ, Husain M (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350.
16. Ban K, Kim K, Cho C, Sauvé M, Diamandis EP, Backx PH et al. (2010). Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520-1531.
17. Barakat GM, Nuwayri-Salti N, Kadi LN, Bitar KM, Al-Jaroudi WA, Bikhazi AB (2011). Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts. Gen Physiol Biophys 30: 34-44.
18. Barragán J, Rodríguez R, Blázquez E (1994). Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 266: E459-E466.
19. Barragán JM, Rodriguez RE, Eng J, Blázquez E (1996). Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67: 63-68.
20. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ (2007). Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293: E1289-E1295.
21. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P et al. (2010). Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376: 431-439.
22. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC (2004). Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27: 699-703.
23. Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen Y et al. (2010). Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3: 512-521.
24. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005). Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151.
25. Bromage DI, Davidson SM, Yellon DM (2014). Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther 143: 305-315.
26. Bugger H, Abel ED (2014). Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57: 660-671.
27. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ et al. (2010). Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33: 1734-1737.
28. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47.
29. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G et al. (2013). Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36: 2346-2350.
30. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W et al. (2012). Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61: 888-896.
31. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S et al. (2011). Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 97: 198-207.
32. Courrèges J, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O et al. (2008). Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 25: 1129-1131.
33. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
34. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K et al. (2010). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375: 2234-2243.
35. Donnelly D (2012). The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 166: 27-41.
36. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84: 3434-3438.
37. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250.
38. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139.
39. Erdogdu Ö, Nathanson D, Sjöholm A˚, Nyström T, Zhang Q (2010). Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325: 26-35.
40. Flint A, Raben A, Astrup A, Holst JJ (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520.
41. Flock G, Baggio LL, Longuet C, Drucker DJ (2007). Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56: 3006-3013.
42. Forst T, Michelson G, Ratter F, Weber M, Anders S, Mitry M et al. (2012). Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 29: 1115-1118.
43. Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S (2012). A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696: 194-202.
44. Gallwitz B, Vaag A, Falahati A, Madsbad S (2010). Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 64: 267-276.
45. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. (2009). Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481.
46. Gardiner S, March J, Kemp P, Bennett T (2008). Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol 154: 60-71.
47. Gardiner S, March J, Kemp P, Bennett T, Baker D (2010). Possible involvement of GLP-1 (9-36) in the regional haemodynamic effects of GLP-1 (7-36) in conscious rats. Br J Pharmacol 161: 92-102.
48. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB et al. (2011). A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab Vasc Dis Res 8: 117-124.
49. Gejl M, Søndergaard H, Stecher C, Bibby BM, Møller N, Bøtker H et al. (2012). Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 97: E1165-E1169.
50. Gill A, Hoogwerf BJ, Burger J, Bruce S, MacConell L, Yan P et al. (2010). Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9: 6.
51. Ginsberg HN (2011). The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care 34 (Suppl. 2): S107-S108.
52. Giorgino F, Leonardini A, Laviola L (2013). Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci 1281: 36-50.
53. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO (2001). Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 102: 81-86.
54. Goyal S, Kumar S, Bijjem KV, Singh M (2010). Role of glucagon-like peptide-1 in vascular endothelial dysfunction. Indian J Exp Biol 48: 61-69.
55. Green B, Mooney M, Gault V, Irwin N, Bailey C, Harriott P et al. (2004). Lys9 for Glu9 substitution in glucagon-like peptide-1 (7-36) amide confers dipeptidyl peptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1 (9-36) amide and exendin (9-39). Metabolism 53: 252-259.
56. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ (2008). GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478: 136-142.
57. Greer JJ, Ware DP, Lefer DJ (2006). Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290: H146-H153.
58. Grieve DJ, Cassidy RS, Green BD (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
59. Gustavson S, Chen D, Somayaji V, Hudson K, Baltrukonis D, Singh J et al. (2011). Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13: 1056-1058.
60. Gutzwiller J, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J et al. (1999). Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 276: R1541-R1544.
61. Haffner SM (2006). The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97: 3-11.
62. Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R et al. (2010). Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298: H1096-H1102.
63. Han SZ, Ouchi Y, Karaki H, Orimo H (1995). Inhibitory effects of insulin on cytosolic Ca2+ level and contraction in the rat aorta endothelium-dependent and -independent mechanisms. Circ Res 77: 673-678.
64. Hattori S (2010). Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 58: 69-73.
65. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N et al. (2013). Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 12: 154.
66. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K (2013). GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 62: 373-381.
67. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K et al. (2009). Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380: 44-49.
68. Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J et al. (2014). Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57: 781-784.
69. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
70. Holst J, Schwartz T, Lovgreen N, Pedersen O, Beck-Nielsen H (1982). Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 7: 529-538.
71. Hopkins N, Cuthbertson D, Kemp G, Pugh C, Green D, Cable N et al. (2013). Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes Metab 15: 770-773.
72. Horváth E, Benko R, Kiss L, Murányi M, Pék T, Fekete K et al. (2009). Rapid 'glycaemic swings' induce nitrosative stress, activate poly (ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 52: 952-961.
73. Huang W, Newby GB, Lewis AL, Stratford PW, Rogers CA, Newby AC et al. (2013). Periadventitial human stem cell treatment reduces vein graft intimal thickening in pig vein-into-artery interposition grafts. J Surg Res 183: 33-39.
74. Hubert HB, Feinleib M, McNamara PM, Castelli WP (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977.
75. Huisamen B, George C, Dietrich D, Genade S (2013). Cardioprotective and anti-hypertensive effects of Prosopis glandulosa in rat models of pre-diabetes: cardiovascular topics. Cardiovasc J Afr 24: 10-16.
76. International Diabetes Federation (2014). IDF Diabetes Atlas Sixth Edition. Available at: http://www.idf.org/diabetesatlas (accessed 5/25/2014).
77. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F et al. (2013). Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 10: 72-77.
78. Kahn AM, Husid A, Odebunmi T, Allen JC, Seidel CL, Song T (1998). Insulin inhibits vascular smooth muscle contraction at a site distal to intracellular Ca2+ concentration. Am J Physiol Endocrinol Metab 274: E885-E892.
79. Kang H, Kang Y, Chun HJ, Jeong J, Park C (2013). Evaluation of the in vitro and in vivo angiogenic effects of exendin-4. Biochem Biophys Res Commun 434: 150-154.
80. Katare R, Riu F, Rowlinson J, Lewis A, Holden R, Meloni M et al. (2013). Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscler Thromb Vasc Biol 33: 1872-1880.
81. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ (2012). Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 11: 64.
82. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S et al. (2013). GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575.
83. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al. (2007). Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286.
84. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD (2010). Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 33: 1028-1030.
85. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP et al. (2008). Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 48: 1389-1399.
86. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM (2014). Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE 9: e97554.
87. Kreymann B, Ghatei M, Williams G, Bloom S (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 330: 1300-1304.
88. Liu H, Dear AE, Knudsen LB, Simpson RW (2009). A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201: 59-66.
89. Liu J, Liu Y, Chen L, Wang Y, Li J (2013). Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J Diabetes Res 2013: 630537.
90. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A et al. (2010). Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9: 76.
91. Liu X, Wei J, Peng DH, Layne MD, Yet SF (2005). Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice. Diabetes 54: 778-784.
92. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB et al. (2012). Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33: 1491-1499.
93. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS et al. (2010). Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 206: 287-296.
94. Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, Bach H et al. (2010). Glucagon-like peptide-1 (1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67: 3549-3555.
95. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning B et al. (2006). Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49: 2049-2057.
96. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E et al. (2012). A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59: 265-276.
97. Matsubara M, Kanemoto S, Leshnower BG, Albone EF, Hinmon R, Plappert T et al. (2011). Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 165: 38-45.
98. Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED et al. (2013). Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 108: 365.
99. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T (2013). Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 305: H295-H304.
100. Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM et al. (2008). Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30: 1448-1460.
101. Morinigo R, Moizé V, Musri M, Lacy AM, Navarro S, Marín JL et al. (2006). Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91: 1735-1740.
102. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J et al. (2011). Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54: 2649-2659.
103. Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S et al. (2008). Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta 390: 38-43.
104. Nathan DM (1996). The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med 124: 86-89.
105. Nathanson D, Erdogdu Ö, Pernow J, Zhang Q, Nyström T (2009). Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 157: 8-13.
106. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. (2009). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84-90.
107. Nauck M, Frid A, Hermansen K, Thomsen A, During M, Shah N et al. (2013). Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15: 204-212.
108. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R et al. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and c-peptide responses. J Clin Endocrinol Metab 63: 492-498.
109. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988.
110. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM (1998a). Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68: 525-530.
111. Näslund E, Grybäck P, Backman L, Jacobsson H, Juul J, Theodorsson HE et al. (1998b). Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43: 945-952.
112. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM (2003). Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. Hypertension 42: 878-884.
113. Nguyen TD, Shingu Y, Amorim PA, Schwarzer M, Doenst T (2013). Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. Int J Cardiol 168: 4085-4092.
114. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. (2004a). Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961.
115. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al. (2004b). Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965.
116. Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408.
117. Noyan-Ashraf MH, Momen MA, Ban K, Sadi A, Zhou Y, Riazi AM et al. (2009). GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
118. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B et al. (2004). Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215.
119. Nyström T, Gonon AT, Sjöholm A, Pernow J (2005). Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125: 173-177.
120. Okerson T, Yan P, Stonehouse A, Brodows R (2010). Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23: 334-339.
121. Özyazgan S, Kutluata N, Afsar S, Özdas S, Akkan A (2005). Effect of glucagon-like peptide-1 (7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74: 119-126.
122. Pabreja K, Mohd M, Koole C, Wootten D, Furness S (2013). Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol 171: 1114-1128.
123. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ et al. (2012). GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154: 127-139.
124. Parlevliet ET, Wang Y, Geerling JJ, Schröder-Van der Elst JP, Picha K, O'Neil K et al. (2012). GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE∗3-Leiden mice. PLoS ONE 7: e49152.
125. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
126. Picatoste B, Ramirez E, Caro-Vadillo A, Iborra C, Egido J, Tuñón J et al. (2013). Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE 8: e78330.
127. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M et al. (2013). Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol 12: 117.
128. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP (2008). Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160.
129. Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P et al. (2014). GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155: 1280-1290.
130. Rask E, Olsson T, Söderberg S, Johnson O, Seckl J, Holst JJ et al. (2001). Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24: 1640-1645.
131. Ravassa S, Zudaire A, Carr RD, Diez J (2011). Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 300: H1361-H1372.
132. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M, Wiklund O et al. (2011). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769-1818.
133. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S et al. (2014). Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63: 1224-1233.
134. Richter G, Feddersen O, Wagner U, Barth P, Goke R, Goke B (1993). GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol 265: L374-L381.
135. Scheen AJ (2013). Cardiovascular effects of gliptins. Nat Rev Cardiol 10: 73-84.
136. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD (2010). Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212: 217-222.
137. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326.
138. Scott R, Wu M, Sanchez M, Stein P (2007). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61: 171-180.
139. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z et al. (2011). Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124: 2338-2349.
140. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M et al. (2012). Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126: 1838-1851.
141. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N et al. (2003). Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 42: 165-172.
142. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M et al. (2012). The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221: 375-382.
143. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006). Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699.
144. Sonne DP, Engstrøm T, Treiman M (2008). Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-249.
145. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993). Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444.
146. Stratton I, Cull C, Adler A, Matthews D, Neil H, Holman R (2006). Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49: 1761-1769.
147. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N et al. (2013). Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 36: 683-689.
148. Timmers L, Henriques JP, de Kleijn DP, DeVries JH, Kemperman H, Steendijk P et al. (2009). Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510.
149. Toft-Nielsen M, Madsbad S, Holst JJ (1999). Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143.
150. Tremblay A, Lamarche B, Deacon CF, Weisnagel S, Couture P (2011). Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13: 366-373.
151. Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D et al. (1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828.
152. Van Gaal LF, Mertens IL, Christophe E (2006). Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
153. Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora MR et al. (2011). Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract 17: 192-200.
154. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB et al. (2001). Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345: 1291-1297.
155. Verdich C, Toubro S, Buemann B, Lysga˚rd Madsen J, Juul Holst J, Astrup A (2001). The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25: 1206-1214.
156. Vergès B, Zeller M, Dentan G, Beer J-C, Laurent Y, Janin-Manificat L et al. (2007). Impact of fasting glycemia on short-term prognosis after acute myocardial infarction. J Clin Endocrinol Metab 92: 2136-2140.
157. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges J-P et al. (2007). Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30: 1608-1610.
158. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D et al. (2013). Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 62: 1697-1708.
159. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327-1335.
160. Willett WC, Dietz WH, Colditz GA (1999). Guidelines for healthy weight. N Engl J Med 341: 427-434.
161. Wright EJ, Farrell KA, Malik N, Kassem M, Lewis AL, Wallrapp C et al. (2012). Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts. Stem Cells Transl Med 1: 759-769.
162. Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR et al. (2013). Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 304: H131-H141.
163. Yoshihara M, Akasaka H, Ohnishi H, Miki T, Furukawa T, Yuda S et al. (2013). Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study. PLoS ONE 8: e67578.
164. Younce CW, Burmeister MA, Ayala JE (2013). Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol 304: C508-C518.
165. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M et al. (2003). Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125-1135.
166. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y-T et al. (2006). Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113.
167. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P et al. (2009). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+ TZD). Diabetes Care 32: 1224-1230.